CSL and uniQure un­veil three-year da­ta for one-time he­mo­phil­ia B gene ther­a­py that costs $3.5M

With its $3.5 mil­lion price tag, CSL Behring and uniQure’s one-off he­mo­phil­ia B gene ther­a­py Hem­genix is one of the world’s most ex­pen­sive ther­a­pies. On Fri­day, three-year fol­low-up from its reg­is­tra­tional study of­fers a new look at the drug’s cu­ra­tive po­ten­tial.

The HOPE-B study test­ed a dose of Hem­genix in 54 men with the rare bleed­ing dis­or­der. The treat­ment se­cured an FDA ap­proval in No­vem­ber 2022 on the ba­sis of topline re­sults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER